ImmunOs Therapeutics
ImmunOs Therapeutics AG is dedicated to developing novel therapeutics that harness the immune system to treat cancer and inflammatory diseases. Their approach is based on identifying specific human leukocyte antigen (HLA) molecules to create biologic therapies that activate the immune system against tumors and autoimmune conditions. The company aims to improve patient outcomes through innovative immunotherapy solutions.
Industries
Nr. of Employees
small (1-50)
ImmunOs Therapeutics
Wagistrasse 14, 8952 Schlieren, Switzerland
Products
Clinical‑stage HLA‑based biologic candidate (lead program)
A clinical‑stage biologic developed from an HLA-based platform that engages innate immune receptors and is being evaluated for treatment of solid tumors; advanced into first‑in‑human studies and combination trial expansions.
Antibody candidates for autoimmune and inflammatory diseases
Antibody programs designed to block activation of disease-associated HLA proteins to reduce pro‑inflammatory responses in indications including ankylosing spondylitis, lupus, psoriasis, and inflammatory bowel disease.
Clinical‑stage HLA‑based biologic candidate (lead program)
A clinical‑stage biologic developed from an HLA-based platform that engages innate immune receptors and is being evaluated for treatment of solid tumors; advanced into first‑in‑human studies and combination trial expansions.
Antibody candidates for autoimmune and inflammatory diseases
Antibody programs designed to block activation of disease-associated HLA proteins to reduce pro‑inflammatory responses in indications including ankylosing spondylitis, lupus, psoriasis, and inflammatory bowel disease.
Services
Research and development of antibodies and biologic molecules that engage or block specific HLA proteins for oncology and autoimmune indications.
Execution of in vitro assays and in vivo animal studies to evaluate anti-tumor activity and pharmacology of candidate biologics.
Management and conduct of first-in-human and Phase I clinical trials, including design of combination studies with approved immunotherapies and collaboration with external clinical partners.
Development of manufacturing-enabling processes, quality controls, and technical development activities to support clinical supply of biologic candidates.
Research and development of antibodies and biologic molecules that engage or block specific HLA proteins for oncology and autoimmune indications.
Execution of in vitro assays and in vivo animal studies to evaluate anti-tumor activity and pharmacology of candidate biologics.
Management and conduct of first-in-human and Phase I clinical trials, including design of combination studies with approved immunotherapies and collaboration with external clinical partners.
Development of manufacturing-enabling processes, quality controls, and technical development activities to support clinical supply of biologic candidates.
Expertise Areas
- Immuno-oncology
- Autoimmune and inflammatory disease therapeutics
- Antibody discovery and protein engineering
- Bispecific biologic design
Key Technologies
- HLA-based biologic therapeutics
- Bispecific antibody constructs
- Antibody engineering
- Protein engineering
News & Updates
On September 17, 2024, ImmunOs Therapeutics AG announced an $11 million funding round to strengthen its investor base.
On July 24, 2024, the company announced the expansion of its Phase I clinical trial for IOS-1002 in combination with pembrolizumab.
On December 11, 2023, the company presented details of its bispecific anti-tumor molecules at the ESMO Congress.
On October 24, 2023, an overview of the Phase 1a/b trial of IOS-1002 was presented.
On October 17, 2023, the company announced a collaboration with Merck & Co. for clinical trials.
On September 19, 2023, Dr. Guenther was appointed to lead CMC and technical development.
On September 17, 2024, ImmunOs Therapeutics AG announced an $11 million funding round to strengthen its investor base.
On July 24, 2024, the company announced the expansion of its Phase I clinical trial for IOS-1002 in combination with pembrolizumab.
On December 11, 2023, the company presented details of its bispecific anti-tumor molecules at the ESMO Congress.
On October 24, 2023, an overview of the Phase 1a/b trial of IOS-1002 was presented.
On October 17, 2023, the company announced a collaboration with Merck & Co. for clinical trials.
On September 19, 2023, Dr. Guenther was appointed to lead CMC and technical development.